CD19, CD20, and BCMA (tri-target)

Class

Autologous tri-target CAR-T cell therapy

Pathway

Chimeric antigen receptor T-cell therapy co-targeting three B-cell/plasma-cell surface antigens simultaneously, designed to limit antigen-escape relapse

CAR-T cell therapy is a form of adoptive cellular immunotherapy in which a patient's own T lymphocytes are collected, genetically engineered to express a synthetic receptor called a chimeric antigen receptor (CAR), then expanded and reinfused. The CAR redirects T-cell killing toward a chosen surface protein, bypassing the need for conventional antigen presentation. This construct targets three surface markers at once: CD19 and CD20, both expressed broadly across the B-cell lineage, and B-cell maturation antigen (BCMA), expressed mainly on plasma cells and plasmablasts. Single-target CAR-T therapies directed at CD19 or BCMA alone have shown that malignant cells can survive treatment by losing or reducing expression of the targeted antigen, a process called antigen escape, a major driver of relapse. By engineering one product to recognize any of three independent markers, the rationale is that tumor cells would need to lose several antigens at once to evade elimination, a much less likely event. This strategy is relevant across B-cell malignancies such as lymphomas and leukemias, and in multiple myeloma, where variation in antigen expression among tumor cells contributes to treatment failure. Overall, tri-targeting aims to improve the durability of response rather than change the underlying killing mechanism.